Clinical Trials Logo
  1. Home
  2. Other
  3. NCT03430895

Evaluating Immune Therapy, Durvalumab (MEDI4736) With Tremelimumab for Metastatic, Non-transitional Cell Carcinoma of the Urinary Tract

Metastatic Bladder Cancer Clinical Trial

Official title:
A Phase II Trial of Durvalumab (MEDI4736) and Tremelimumab in Metastatic, Non-transitional Cell Carcinoma of the Urothelial Tract

Clinical Trial Summary

This study is being done test to test the safety and effectiveness of durvalumab combined with tremelimumab in patients who have a rare form of cancer of the urinary tract.

Clinical Trial Description

n/a

Study Design

Related Conditions & MeSH terms

Clinical Trial Details
NCT number NCT03430895
Study type Interventional
Source Memorial Sloan Kettering Cancer Center
Contact
Status Completed
Phase Phase 2
Start date January 31, 2018
Completion date February 10, 2021
View Details
See also
  Status Clinical Trial Phase
Completed NCT02028442 - Phase I / II Study of Enadenotucirev by Sub-acute Fractionated IV Dosing in Cancer Patients Phase 1/Phase 2
Completed NCT01454089 - A Phase 2 Study Comparing Chemotherapy in Combination With OGX-427 or Placebo in Patients With Bladder Cancer Phase 2
Recruiting NCT06138561 - Management of Cisplatin-Ineligible Patients With Metastatic Bladder Cancer and The Role of Geriatric Assessments
Terminated NCT04887831 - Trilaciclib, a CDK 4/6 Inhibitor, in Patients With Advanced/Metastatic Bladder Cancer Receiving Chemotherapy Then Avelumab Phase 2
Recruiting NCT06129084 - A Study to Compare the Results of FGFR Testing by Either ctDNA Blood Testing or Standard Tumor Tissue Testing
Recruiting NCT05259319 - Study Evaluating the Safety and the Efficacy of Combination of Atezolizumab, Tiragolumab and and Stereotactic Body Radiation Therapy in Patients With Oligometastatic Multiorgan (IMMUNOs-SBRT) Phase 1
Completed NCT02030067 - Dose-Finding and Safety Study for Oral Single-Agent to Treat Advanced Malignancies Phase 1/Phase 2
Active, not recruiting NCT02989584 - A Phase II Study of Atezolizumab in Combination With Cisplatin + Gemcitabine Before Surgery to Remove the Bladder Cancer Phase 1/Phase 2
Completed NCT04200963 - A Phase 1a/b Study of IK-175 as a Single Agent and in Combination With Nivolumab in Patients With Locally Advanced or Metastatic Solid Tumors and Urothelial Carcinoma Phase 1
Terminated NCT03498196 - A Window of Opportunity Trial: Avelumab in Non-metastatic Muscle Invasive Bladder Cancer Phase 1/Phase 2
Not yet recruiting NCT01814150 - The Association Between Alpha 1 Acid Glycoprotein Level and Outcome Metastatic Cancer Treated With Docetaxel N/A